Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small…
Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5%…
PR Newswire is a distributor of press releases headquartered in New York City.